secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019641
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q1 net loss $17.5M; first patient dosed with JANX008 in Phase 1
---------------------------------------------------------------------

- Cash and equivalents $316.9M, down from $327.0M at Dec 31, 2022.
- R&D expenses $15.9M (up from $10.2M); G&A $6.5M (up from $4.9M).
- First patient enrolled in EGFR-TRACTr (JANX008) Phase 1 for solid tumors.
- Interim clinical update for PSMA-TRACTr (JANX007) expected in 2H 2023.
- PD-L1xCD28 TRACIr (JANX009) IND on track for submission in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023019641/0000950170-23-019641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023019641/janx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer